Quality

  1. Home
  2. Products
  3. Customized ADCs
  4. LYPD3
  5. Anti-LYPD3-auristatin ADC

Anti-LYPD3-auristatin ADC (ADC-W-561)

This ADC product is comprised of an anti-C44a monoclonal antibody conjugated via a linker to auristatin. The auristatin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, auristatin binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

 ADC Target

  • Name
  • LYPD3
  • Alternative Names
  • LYPD3; LY6/PLAUR Domain Containing 3;GPI-Anchored Metastasis-Associated Protein C4.4A Homolog;Matrigel-Induced Gene C4 Protein;MIG-C4;GPI-Anchored Metastasis-Associated Protein Homolog;Ly6/PLAUR Domain-Containing Protein 3;2310061G07Rik;
  • Target Entrez Gene ID
  • 27076
  • Overview
  • This gene is a Protein Coding gene. GO annotations related to this gene include laminin binding. An important paralog of this gene is LYPD5.

 ADC Antibody

  • Overview
  • Anti-LYPD3 Antibody
  • Species Reactivity
  • Human

 ADC payload drug

  • Name
  • Auristatin
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:









Customized FluoroAb™

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
USA
 
 Tel:
 Fax:
 Email:
Europe
 
 Tel:
 Email:
Germany
 
 Tel:
 Email:


Inquiry

Top